Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$13.74 -4.6%	$14.00	$7.86 ▼ $17.75	$1.64B	1.76	2.21 million shs	2.34 million shs
BEAM Beam Therapeutics	$16.80 -2.0%	$17.69	$13.53 ▼ $35.25	$1.69B	2.08	1.49 million shs	4.49 million shs
PFNX Pfenex	$12.75	$12.75	$5.26 ▼ $14.00	$437.29M	N/A	503,865 shs	N/A
TARS Tarsus Pharmaceuticals	$40.35 +0.0%	$44.24	$20.08 ▼ $57.28	$1.70B	0.83	689,504 shs	951,826 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	0.00%	-0.58%	+0.51%	-12.65%	+47.90%
BEAM Beam Therapeutics	0.00%	+0.24%	+2.94%	-24.36%	-32.37%
PFNX Pfenex	0.00%	0.00%	0.00%	0.00%	0.00%
TARS Tarsus Pharmaceuticals	0.00%	-0.74%	-7.11%	-22.01%	+59.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	1.973 of 5 stars	3.4	1.0	0.0	0.0	2.2	1.7	0.6
BEAM Beam Therapeutics	2.2546 of 5 stars	3.5	1.0	0.0	0.0	2.0	2.5	0.6
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	2.2346 of 5 stars	3.5	0.0	0.0	0.0	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.83	Moderate Buy	$18.80	36.83% Upside
BEAM Beam Therapeutics	3.00	Buy	$48.75	190.18% Upside
PFNX Pfenex	0.00	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	65.22% Upside

Current Analyst Ratings Breakdown

Latest PFNX, TARS, BEAM, and ARQT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
5/27/2025	TARS Tarsus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$72.00
5/23/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
5/5/2025	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$46.00 ➝ $51.00
5/2/2025	TARS Tarsus Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $84.00
4/9/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/7/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/3/2025	ARQT Arcutis Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$196.54M	8.33	N/A	N/A	$1.35 per share	10.18
BEAM Beam Therapeutics	$63.52M	26.60	N/A	N/A	$8.86 per share	1.90
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	$182.95M	9.27	N/A	N/A	$5.87 per share	6.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$140.04M	-$1.04	N/A	N/A	N/A	-60.95%	-80.66%	-32.94%	8/13/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
PFNX Pfenex	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.73	N/A	N/A	N/A	-44.91%	-39.72%	-25.74%	8/6/2025 (Estimated)

Latest PFNX, TARS, BEAM, and ARQT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	ARQT Arcutis Biotherapeutics	-$0.21	-$0.20	+$0.01	-$0.20	$64.80 million	$65.85 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.75	3.55	3.37
BEAM Beam Therapeutics	N/A	8.81	8.81
PFNX Pfenex	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	0.21	5.57	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
BEAM Beam Therapeutics	99.68%
PFNX Pfenex	N/A
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
BEAM Beam Therapeutics	3.50%
PFNX Pfenex	N/A
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.20 million	108.00 million	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
PFNX Pfenex	71	34.30 million	N/A	Not Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	38.25 million	Optionable

PFNX, TARS, BEAM, and ARQT Headlines

Recent News About These Companies

Brokerages Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $66.67

June 20, 2025 | americanbankingnews.com

Tarsus Pharmaceuticals Becomes Oversold (TARS)

June 19, 2025 | nasdaq.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by GAMMA Investing LLC

June 19, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Brokerages

June 17, 2025 | marketbeat.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Assenagon Asset Management S.A. Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 12, 2025 | marketbeat.com

E. Ohman J or Asset Management AB Boosts Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 7, 2025 | marketbeat.com

Squarepoint Ops LLC Sells 51,329 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 7, 2025 | marketbeat.com

Stocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS Rating

June 6, 2025 | msn.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Time to Sell?

June 5, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 5, 2025 | marketbeat.com

Wellington Management Group LLP Sells 8,552 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 4, 2025 | marketbeat.com

Tarsus Pharmaceuticals assumed with an Outperform at Oppenheimer

June 2, 2025 | msn.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Oppenheimer

June 2, 2025 | marketbeat.com

Nuveen Asset Management LLC Sells 15,186 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 31, 2025 | marketbeat.com

Q2 Earnings Forecast for TARS Issued By HC Wainwright

May 30, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Ameriprise Financial Inc.

May 30, 2025 | marketbeat.com

Tarsus to Participate in Upcoming Investor Conferences

May 29, 2025 | globenewswire.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Lessened by Two Sigma Advisers LP

May 29, 2025 | marketbeat.com

Two Sigma Investments LP Has $5.05 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFNX, TARS, BEAM, and ARQT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$13.74 -0.66 (-4.58%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.86 +0.13 (+0.91%)

As of 06/27/2025 07:33 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Beam Therapeutics NASDAQ:BEAM

$16.80 -0.34 (-1.98%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$16.84 +0.04 (+0.27%)

As of 06/27/2025 07:56 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)

As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Tarsus Pharmaceuticals NASDAQ:TARS

$40.35 +0.02 (+0.05%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$40.35 +0.00 (+0.01%)

As of 06/27/2025 05:31 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time